Prestige Consumer Healthcare raised its fiscal 2027 revenue guidance to $1.29 billion to $1.315 billion, incorporating the completed acquisitions of Breathe Right and LaCorium Health, the company said in its first-quarter earnings announcement.
Prestige closed the Breathe Right acquisition in June 2026 and the LaCorium Health deal in July 2026. The two acquisitions combined add new product lines to Prestige's portfolio of over-the-counter consumer health brands, which include BC and Goody's pain relievers, Nix lice treatment, and Dramamine motion sickness medication. The company also raised $400 million in senior notes during the LaCorium integration process to fund the combined deals.
Breathе Right, a nasal strip brand owned by GlaxoSmithKline before the deal, addresses a consumer sleep and breathing category. LaCorium Health operates in women's health and specialty care. Prestige said the acquisitions are expected to contribute materially to earnings in fiscal 2027, though the company did not break out standalone contribution figures from either deal in the guidance.
The revised outlook reflects Prestige's expectation that both businesses will operate under its existing management structure through the fiscal year, which ends in September 2027. The company reported first-quarter fiscal 2027 results on the same day as the guidance update, positioning the raised forecast as its full-year view following eight weeks of combined operations across the two acquisitions.
Prestige trades as PBH on the New York Stock Exchange. The company has pursued acquisitions over the past three years to diversify revenue beyond its traditional cold and pain remedy business, which faces secular decline as consumers shift to digital health services and lower-priced private-label alternatives.
The guidance range of $1.29 billion to $1.315 billion represents a midpoint of $1.3025 billion, a 15 percent increase over Prestige's fiscal 2026 reported revenue, though that comparison includes a full year of both acquisitions versus their partial-year contribution. Prestige said the two deals generated combined annual revenue of roughly $400 million to $450 million on a run-rate basis before cost reductions.
The number that decides whether the integration succeeds is whether Prestige achieves the promised cost reductions it cited during the acquisition announcements. If the company reports cost reductions below 70 percent of its original targets by the end of fiscal 2027, execution risk in the combined operations would become material.
